Inhibrx

$19.14
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.25 (+1.32%) Today
$0.00 (0.00%) As of 6:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Inhibrx and other stocks, options, and ETFs commission-free!

About INBX

Inhibrx, Inc. Common Stock, also called Inhibrx, is a clinical stage company, which focuses on developing pipeline of novel biologic therapeutic candidates. Read More The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA. The listed name for INBX is Inhibrx, Inc. Common Stock.

Employees
95
Headquarters
La Jolla, California
Founded
2010
Market Cap
721.77M
Price-Earnings Ratio
Dividend Yield
Average Volume
47.59K
High Today
$19.69
Low Today
$18.41
Open Price
$18.99
Volume
39.72K
52 Week High
$26.98
52 Week Low
$15.42

Collections

You May Also Like